NASDAQ:CMPX Compass Therapeutics (CMPX) Stock Forecast, Price & News $3.14 +0.11 (+3.63%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$3.00▼$3.1950-Day Range$2.64▼$3.4852-Week Range$1.81▼$5.65Volume360,551 shsAverage Volume302,178 shsMarket Capitalization$397.24 millionP/E RatioN/ADividend YieldN/APrice Target$9.05 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Compass Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.0% Downside$0.00 Price TargetShort InterestHealthy3.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.19Based on 2 Articles This WeekInsider TradingAcquiring Shares$33,700 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.34) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.23 out of 5 starsMedical Sector179th out of 988 stocksBiological Products, Except Diagnostic Industry24th out of 161 stocks 0.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $0.00, Compass Therapeutics has a forecasted downside of 100.0% from its current price of $3.14.Amount of Analyst CoverageCompass Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.05% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Compass Therapeutics has recently decreased by 5.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCompass Therapeutics does not currently pay a dividend.Dividend GrowthCompass Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMPX. Previous Next 2.9 News and Social Media Coverage News SentimentCompass Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Compass Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CMPX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compass Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $33,700.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders29.80% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.27% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.34) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Therapeutics is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Therapeutics is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompass Therapeutics has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Compass Therapeutics (NASDAQ:CMPX) StockCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.Read More Receive CMPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPX Stock News HeadlinesJune 3, 2023 | americanbankingnews.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives $9.05 Consensus Price Target from AnalystsJune 1, 2023 | finance.yahoo.comCompass Therapeutics to Participate in Upcoming Investor EventsJune 10, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.June 1, 2023 | americanbankingnews.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Sees Significant Decline in Short InterestMay 31, 2023 | americanbankingnews.comHead-To-Head Contrast: argenx (NASDAQ:ARGX) vs. Compass Therapeutics (NASDAQ:CMPX)May 11, 2023 | americanbankingnews.comBrokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) PT at $9.05May 10, 2023 | americanbankingnews.comFY2027 EPS Estimates for Compass Therapeutics, Inc. (NASDAQ:CMPX) Lifted by WedbushMay 10, 2023 | americanbankingnews.comHead to Head Review: BioAtla (NASDAQ:BCAB) vs. Compass Therapeutics (NASDAQ:CMPX)June 10, 2023 | Vector Vest (Ad)Free Stock Analysis Report: See The True Value of Any StockGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. May 10, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Compass Therapeutics (CMPX)May 9, 2023 | americanbankingnews.comHC Wainwright Equities Analysts Raise Earnings Estimates for Compass Therapeutics, Inc. (NASDAQ:CMPX)May 4, 2023 | msn.comCompass Therapeutics: Q1 Earnings InsightsMay 4, 2023 | finance.yahoo.comCompass Therapeutics Reports First Quarter Financial Results and Provides Corporate UpdateApril 26, 2023 | finance.yahoo.comCompass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQApril 25, 2023 | usnews.comFrequently Asked Questions: U.S. News College CompassApril 19, 2023 | finance.yahoo.comCompass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology DaysApril 16, 2023 | americanbankingnews.comCompass Therapeutics (NASDAQ:CMPX) vs. Sutro Biopharma (NASDAQ:STRO) Financial ComparisonApril 16, 2023 | americanbankingnews.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Recommendation of "Buy" from BrokeragesApril 13, 2023 | finance.yahoo.comWith 55% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional ownersMarch 31, 2023 | americanbankingnews.comFinancial Review: Valneva (NASDAQ:VALN) & Compass Therapeutics (NASDAQ:CMPX)March 28, 2023 | finance.yahoo.comCompass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology SymposiumMarch 22, 2023 | americanbankingnews.comSVB Leerink Equities Analysts Boost Earnings Estimates for Compass Therapeutics, Inc. (NASDAQ:CMPX)March 21, 2023 | americanbankingnews.comEquities Analysts Issue Forecasts for Compass Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CMPX)March 21, 2023 | americanbankingnews.comHC Wainwright Weighs in on Compass Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CMPX)March 17, 2023 | seekingalpha.comCompass Therapeutics GAAP EPS of -$0.10March 17, 2023 | finance.yahoo.comWe're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash WiselyMarch 15, 2023 | finance.yahoo.comCompass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateSee More Headlines CMPX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMPX Company Calendar Last Earnings3/15/2023Today6/10/2023Next Earnings (Estimated)8/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMPX CUSIPN/A CIK1738021 Webwww.compasstherapeutics.com Phone617-500-8099FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Forecast$0.00 High Stock Price Forecast$0.00 Low Stock Price Forecast$10,000,000.00 Forecasted Upside/Downside+188.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.60% Return on Assets-24.34% Debt Debt-to-Equity RatioN/A Current Ratio16.41 Quick Ratio16.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.44 per share Price / Book2.18Miscellaneous Outstanding Shares126,510,000Free Float88,808,000Market Cap$397.24 million OptionableNot Optionable Beta0.71 Key ExecutivesDr. Thomas J. Schuetz M.D. (Age 62)Ph.D., Co-Founder, CEO & Director Comp: $829.56kDr. Vered Bisker-Leib M.D. (Age 51)MBA, Ph.D., Pres & COO Comp: $806.43kMr. Neil L. Lerner CPA (Age 56)VP of Fin. Mr. Jonathan Anderman J.D.VP, Head of Legal & Corp. Sec.Anna GiffordCommunications Mang.Dr. Minori Rosales M.D. (Age 60)Ph.D., Sr. VP & Head of Clinical Devel. Ms. Karin Herrera B.A.VP & Head of Clinical OperationsMore ExecutivesKey CompetitorsFusion PharmaceuticalsNASDAQ:FUSNRallybioNASDAQ:RLYBFoghorn TherapeuticsNASDAQ:FHTXCarisma TherapeuticsNASDAQ:CARMTenaya TherapeuticsNASDAQ:TNYAView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 93,315 shares on 5/16/2023Ownership: 0.698%Fred Alger Management LLCSold 205,474 shares on 5/16/2023Ownership: 0.319%State Street CorpBought 132,200 shares on 5/16/2023Ownership: 0.318%Jane Street Group LLCBought 319,556 shares on 5/16/2023Ownership: 0.302%Squarepoint Ops LLCBought 16,263 shares on 5/16/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions CMPX Stock - Frequently Asked Questions Should I buy or sell Compass Therapeutics stock right now? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" CMPX shares. View CMPX analyst ratings or view top-rated stocks. What is Compass Therapeutics' stock price forecast for 2023? 0 Wall Street analysts have issued 12-month target prices for Compass Therapeutics' stock. Their CMPX share price forecasts range from $10,000,000.00 to $0.00. On average, they expect the company's share price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%. View analysts price targets for CMPX or view top-rated stocks among Wall Street analysts. How have CMPX shares performed in 2023? Compass Therapeutics' stock was trading at $5.03 at the beginning of the year. Since then, CMPX stock has decreased by 37.6% and is now trading at $3.14. View the best growth stocks for 2023 here. When is Compass Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023. View our CMPX earnings forecast. How were Compass Therapeutics' earnings last quarter? Compass Therapeutics, Inc. (NASDAQ:CMPX) released its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. When did Compass Therapeutics IPO? (CMPX) raised $50 million in an IPO on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel served as the underwriters for the IPO and Raymond James was co-manager. What is Compass Therapeutics' stock symbol? Compass Therapeutics trades on the NASDAQ under the ticker symbol "CMPX." Who are Compass Therapeutics' major shareholders? Compass Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (4.49%), Foresite Capital Management V LLC (2.75%), Braidwell LP (2.57%), Monashee Investment Management LLC (1.72%), BlackRock Inc. (1.22%) and Geode Capital Management LLC (0.70%). Insiders that own company stock include Carl L Gordon, Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib. View institutional ownership trends. How do I buy shares of Compass Therapeutics? Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Compass Therapeutics' stock price today? One share of CMPX stock can currently be purchased for approximately $3.14. How much money does Compass Therapeutics make? Compass Therapeutics (NASDAQ:CMPX) has a market capitalization of $397.24 million. The company earns $-39,220,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. How can I contact Compass Therapeutics? The official website for the company is www.compasstherapeutics.com. The company can be reached via phone at 617-500-8099 or via email at ir@compasstherapeutics.com. This page (NASDAQ:CMPX) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.